Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015

DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/tb22l6/cancer_cd) has announced the addition of the "Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015" report to their offering. Pharmaceutical companies are continuously looking for better therapeutic options to effectively cure and prevent various malignancies. Buy Skelaxin (Metaxalone Mr) with free prescription Several options for cancer treatment are available belonging to various classes of molecules. About Diflucan (Fluconazole) with free prescription Different types of cancer have different pathophysiological characteristics due to which distinctive approach is required for effective treatment. About Sumycin (Tetracycline) Several molecules have been discovered out of which CD antigens have been found to play an important role in cancer progression and proliferation. Enapril without prescription Investigators are trying to assign different functions to CD antigens by doing extensive research and development. Prograf (Tacrolimus) with no prescription Their role in cancer development has been noted due to which lots of progress would be observed in this segment. Buy Bacopin online Most of the work has been done in cancer segment and pharmacological profiles are expected to be improved in coming years. CD antigen cancer therapeutics have diverse design and target due to which they could be used for several malignancies. http://anti-infectives-opinion.blogspot.com Presence of BiTEs, ADC, monoclonal antibodies and tri-functional antibodies for targeting different CD antigens has been commercialized. Next step is assumed to be the improvement in design as complexity at molecular levels makes it difficult to manufacture them in large quantities. This issue not only decreases the productivity but also increases the cost of production. Higher cost of end products limits the number of cancer patients choosing them as a part of their regular therapeutic regime. With the use of advanced technology it is expected that this issue would be overcome in coming years. Some of the progress could be observed in case of monoclonal antibodies and same scenario could be observed for other CD antigen cancer therapeutics in coming years. Clinical trials are being instigated across the globe in order to extend their utilities in different malignancies. They are versatile in nature due to which they could be used as a part of combinatorial therapy along with monoclonal antibodies. Their utilities in different malignancies are also being studied but results of such clinical trials remains elusive. They have strong clinical pipeline due to which several products would be introduced in coming years. However, these products are at different stages of clinical pipeline and they may take long winding times as lots of experiments proving their safety and efficacy has to be done. With time more CD antigens are expected to be discovered and they would help in the increased market size. Commercial success of marketed CD antigen cancer therapeutics shows that they would be generating significant revenues in coming years. CD antigen cancer market is expected to witness introduction of several products which will help the pharmaceutical companies to generate significant revenues. Increasing demand for better therapeutics, large unmet medical necessities and large numbers of cancer patient s patient are expected to be responsible for the growth of this market segment. Increased funding in research and development along with utilization of advanced technology will also help in increasing their market shares across the globe. Numerous innovative CD antigen cancer therapeutics are at different stages of clinical trials which would increase their market shares. Despite these facts they have higher prices and their manufacturing is difficult but utilization of advanced technology along with streamlining of various processes are expected to overcome this barrier. In this way, future of CD antigen cancer therapeutics looks optimistic due to their superior pharmacological profiles. CD Antigens Segments in Report: CD3, CD4, CD9, CD11, CD19, CD20, CD22, CD26, CD27, CD28, CD29, CD33, CD37, CD40, CD44, CD45, CD47, CD52, CD55, CD56, CD66, CD70, CD74, CD80, CD95, CD98, CD100, CD117, CD135, CD137, CD152, CD200, CD223, CD227, CD246, CD248, CD274, CD276, CD279 Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015 Report Highlight: - Nomenclature & Classification of CD Antigens - Mechanism of CD Antigen Cancer Therapeutics - Cancer CD Antigen Therapy Market Overview - Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase - Cancer CD Antigen Inhibitors Clinical Pipeline: 207 Drugs - Marketed Cancer CD Antigen Inhibitors: 27 Drugs - Majority of Cancer CD Antigen Inhibitors in Preclinical Phase: 70 Drugs - Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 44 Drugs - Cancer CD Antigens Clinical Pipeline is Represented in 52 Graphs & Charts Companies Mentioned - ARIAD Pharmaceuticals - AXXO - Alexion Pharmaceuticals - AryoGen Biopharma - Bayer HealthCare - Biocad - Biogen - Biotecnol Inc. - Bristol-Myers Squibb - Chugai Pharmaceutical - Dr Reddy s Laboratories - Eisai Co Ltd - Emergent BioSolutions - Genmab - ImmunoGen - Intas Biopharmaceuticals - MacroGenics - MedImmune - Merck - Novartis - Ono Pharmaceutical - Onyx Pharmaceuticals - PROBIOMED - Pfizer - Roche - UCB - Xencor For more information visit .researchandmarkets.com/research/tb22l6/cancer_cd

CHMP recommends label update for Giotrif® with addition of data demonstrating overall survival benefit for patients with EGFR mutation-positive lung cancer

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for an update to the European label for Giotrif® (afatinib*), strengthening and broadening the efficacy profile based on additional Phase III data. About Rheumatrex (Methotrexate) with free prescription The CHMP recommendation includes data from the LUX-Lung 3 and 6 trials which showed patients whose tumours have the most common EGFR mutation (deletion in exon 19; del19) lived more than one year longer when treated with first-line Giotrif® compared to standard chemotherapy (overall survival; OS = secondary endpoint, progression-free survival; PFS = primary endpoint). Dr. Elocon (Mometasone) without prescription Mehdi Shahidi, Medical Head, Solid Tumour Oncology, Boehringer Ingelheim commented, “This update to the European label reinforces the importance of Giotrif® as a targeted treatment for patients with EGFR mutation-positive NSCLC, especially for those whose tumours harbor the most common mutation, del19. About Macrobid (nitrofurantoin monohydrate) with no Rx Giotrif® is the first and only targeted agent to date to have shown an overall survival benefit for these patients in the first-line setting.” Following CHMP positive opinion, the European prescribing information will now be updated to include additional data from LUX-Lung 3 and LUX-Lung 6. Eldepryl with no Rx Both studies met the primary endpoint of PFS for patients whose tumours have common EGFR mutations receiving first-line Giotrif®. Retin-A (Tretinoin) with free prescription In addition to new OS data, updated PFS data from the two trials will also be reflected in the updated European label, as will the significant improvements in lung cancer-related symptoms (cough, shortness of breath, pain) and quality of life observed with Giotrif® compared to chemotherapy. Adverse events for Giotrif® in the LUX-Lung 3 and 6 trials were as expected with EGFR inhibition and were predictable, manageable and reversible. Buy Appetite Suppressants online Diarrhoea and rash/acne were the most frequently reported side effects with Giotrif® therapy. NSCLC is the most common form of lung cancer comprising over 85% of lung cancer cases. http://cardiobloodreview.wordpress.com EGFR mutation-positive NSCLC is a subtype of lung cancer. EGFR mutations are found in 10-15% of Caucasian and 40% of Asian patients with NSCLC. There are different types of EGFR mutations; the most common, which account for 90% of all EGFR mutations being del19 (approx. 50%) and L858R (approx. 40%). Afatinib, an oral, once daily ErbB family blocker, is currently approved in more than 60 countries for the first-line treatment of specific types of EGFR mutation-positive NSCLC (under brand names: Giotrif® / Gilotrif®). *Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF® and in the US under the brand name GILOTRIF® for use in patients with specific types of EGFR mutation-positive NSCLC. Registration conditions differ internationally, please refer to locally approved prescribing information. Afatinib is under regulatory review by health authorities in other countries worldwide. Afatinib is not approved in other indications. For notes to editors and references, please visit: .boehringer-ingelheim.com/news/news_releases/press_releases/2015/19_august_2015_oncology.html Intended audiences: This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business. Further Media Channels .facebook.com/boehringeringelheim .twitter.com/Boehringer .youtube.com/user/boehringeringelheim

China Ribonucleic Acid II (RNAII) for Injection Market Investigation Report 2010-2019

. About Suprax (Cefixime) without Rx DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/bxl5pl/investigation) has announced the addition of the "Investigation Report on China s ribonucleic acid II (RNAII) for Injection, 2010-2019" report to their offering. RNAII for injection, one kind of immunomodulator, can improve body immunity and inhibit tumor by causing vacuolar degeneration and colliquative necrosis in tumor cells as well as generating large amounts of hyperplastic fibroblasts, macrophages, lymphocytes or even connective tissue to substitute tumor tissue. Buy Weight Loss online About Noroxin (Norfloxacin) with no prescription And it is used for the adjuvant treatment of pancreatic cancer, liver cancer, stomach cancer, breast cancer, soft tissue sarcoma and other cancers especially hepatitis B. http://allegra-opinion.blogspot.com About Isordil Sublingual (Isosorbide Dinitrate) with no Rx RNAII for injection can also be used for the treatment of various diseases caused by low immune function. According to the market survey, RNAII for injection develops fast in China with sales value rising from less than CNY 60 million in 2005 to about CNY 500 million in 2014 and CAGR during this period reaching 80%. With the lifestyle changes brought about by economic development as well as the serious environmental pollution, the incidence of cancer keeps increasing with the number of new cases exceeding 3 million each year in China. Cycrin (Medroxyprogesterone ) with no prescription Meanwhile, there are over 90 million hepatitis B patients in China too. Dovonex without prescription Therefore, the market size of RNAII for injection is expected to keep growing in the next few years in China. Key Topics Covered: 1 Related Concepts of RNAII for Injection 2 Market Profile of RNAII for Injection in China 3 Survey on Sales Status of RNAII for Injection in China, 2010-2014 4 Survey on Market Share of Major Manufacturers of RNAII for Injection in China, 2010-2014 5 Survey on Dosage Forms of RNAII for Injection in China, 2010-2014 6 Reference Price of RNAII for Injection in Chinese Hospitals in 2014 7 Major Manufacturers of RNAII for Injection in Chinese Market, 2010-2014 8 Market Outlook of RNAII for Injection in China, 2015-2019 Companies Mentioned - Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd - Nanjing Xinbai Pharmaceutical Co., Ltd - Xinxiang Dongsheng Pharmaceutical Co., Ltd For more information visit .researchandmarkets.com/research/bxl5pl/investigation